KEY POINTS
- Crinetics (NASDAQ:CRNX) nearly doubled, jumping about 98% to near US$83, after Vertex agreed to buy it.
- Vertex is paying US$85.00 per share in cash, valuing Crinetics at around US$10 billion.
- The prize is Crinetics' acromegaly drug PALSONIFY and a promising phase 3 treatment, with combined peak sales potential above US$5 billion.
- In our view, the big gain is done: with the stock near the fixed US$85 offer, most of the reward is already in the price.
Crinetics (NASDAQ:CRNX) nearly doubled on Tuesday, soaring about 98% to near US$83, after Vertex Pharmaceuticals agreed to buy the company in an all-cash deal. Vertex is paying US$85.00 per share, valuing Crinetics at roughly US$10 billion. For shareholders, this is a massive overnight win. But the more useful question for investors now is not why the stock jumped; it is what, if anything, is left to gain from here.
Why Vertex Is Paying US$10 Billion for Crinetics
Here is what Vertex is really buying. Crinetics makes PALSONIFY, a once-daily pill approved to treat acromegaly, a rare hormone disorder. It is the first oral therapy of its kind, which matters because patients currently rely on regular injections, so a simple pill is a big improvement. Vertex believes PALSONIFY has “blockbuster” potential, meaning sales that could top US$1 billion a year.
There is a second prize too. Crinetics has a treatment called atumelnant in late-stage (phase 3) trials for another rare hormone condition. Together, these two drugs carry peak sales potential of more than US$5 billion a year. In our view, that explains the rich price: Vertex is paying up now to lock in future growth in rare diseases, an area where treatments command high prices and face little competition.
- Updated
- INSIDER CONVICTION TRADES FY26
The market hasn't noticed yet.
Disclosed by law. Missed by most investors. 129 trades tracked by us.
NO Credit card
- Director buys & sells tracked
- Buy / Hold / Sell verdict on every stock
- Technical analysis included
What the Takeover Reveals About the Biotech Deal Market
This deal is worth noting for a bigger reason. Large drugmakers like Vertex are sitting on huge cash piles and face a looming “patent cliff,” where older blockbuster drugs lose protection and rivals can copy them. The implication is clear: to keep growing, these giants must buy smaller companies with promising new drugs.
That makes this more than a one-off. Crinetics is exactly the kind of target the market has been expecting big pharma to chase: a company with an approved drug plus a strong pipeline. For investors, it is a reminder that small and mid-sized biotechs with genuine, approved products can become takeover targets, often at big premiums to their trading price.
The Investor’s Takeaway for CRNX
So what should investors do now? Here is the key point that many chasing the stock today will miss. Once a cash takeover is announced, the shares stop trading on the business and start trading like the offer itself. Crinetics is already near the US$85 price Vertex will pay, so the huge gain has largely happened.
We believe the easy money is made. From here, the only remaining upside is the small gap to US$85, plus the modest risk the deal falls through on regulatory or shareholder approval, though management from both sides has approved it and closing is expected this quarter (Q3 2026).
For existing holders, this is a strong result and a reasonable point to take profits. For new investors, buying now means locking in a tiny return for real deal risk, which rarely makes sense.
Want to know which ASX and US small caps could be the next takeover targets? Sign up to our free newsletter for our latest analysis and top picks.
